Cross-species single-cell RNA sequencing reveals divergent phenotypes and activation states of adaptive immunity in human carotid and experimental murine atherosclerosis.

Atherosclerosis Immunity Leukocytes Prediction Transcriptome scRNA-seq

Journal

Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427

Informations de publication

Date de publication:
23 Jul 2024
Historique:
received: 16 11 2023
revised: 07 05 2024
accepted: 23 05 2024
medline: 23 7 2024
pubmed: 23 7 2024
entrez: 23 7 2024
Statut: aheadofprint

Résumé

The distinct functions of immune cells in atherosclerosis have been mostly defined by preclinical mouse studies. Contrastingly, the immune cell composition of human atherosclerotic plaques and their contribution to disease progression is only poorly understood. It remains uncertain whether genetic animal models allow for valuable translational approaches. Single cell RNA-sequencing (scRNA-seq) was performed to define the immune cell landscape in human carotid atherosclerotic plaques. The human immune cell repertoire demonstrated an unexpectedly high heterogeneity and was dominated by cells of the T-cell lineage, a finding confirmed by immunohistochemistry. Bioinformatical integration with 7 mouse scRNA-seq data sets from adventitial and atherosclerotic vascular tissue revealed a total of 51 identities of cell types and differentiation states, of which some were only poorly conserved between species and exclusively found in humans. Locations, frequencies, and transcriptional programs of immune cells in mouse models did not resemble the immune cell landscape in human carotid atherosclerosis. In contrast to standard mouse models of atherosclerosis, human plaque leukocytes were dominated by several T-cell phenotypes with transcriptional hallmarks of T-cell activation and memory formation, T-cell receptor-, and pro-inflammatory signaling. Only mice at the age of 22 months partially resembled the activated T-cell phenotype. In a validation cohort of 43 patients undergoing carotid endarterectomy, the abundance of activated immune cell subsets in the plaque defined by multi-color flow cytometry associated with the extend of clinical atherosclerosis. Integrative scRNA-seq reveals a substantial difference in the immune cell composition of murine and human carotid atherosclerosis - a finding that questions the translational value of standard mouse models for adaptive immune cell studies. Clinical associations suggest a specific role for T-cell driven (auto-) immunity in human plaque formation and -instability.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
The distinct functions of immune cells in atherosclerosis have been mostly defined by preclinical mouse studies. Contrastingly, the immune cell composition of human atherosclerotic plaques and their contribution to disease progression is only poorly understood. It remains uncertain whether genetic animal models allow for valuable translational approaches.
METHODS AND RESULTS RESULTS
Single cell RNA-sequencing (scRNA-seq) was performed to define the immune cell landscape in human carotid atherosclerotic plaques. The human immune cell repertoire demonstrated an unexpectedly high heterogeneity and was dominated by cells of the T-cell lineage, a finding confirmed by immunohistochemistry. Bioinformatical integration with 7 mouse scRNA-seq data sets from adventitial and atherosclerotic vascular tissue revealed a total of 51 identities of cell types and differentiation states, of which some were only poorly conserved between species and exclusively found in humans. Locations, frequencies, and transcriptional programs of immune cells in mouse models did not resemble the immune cell landscape in human carotid atherosclerosis. In contrast to standard mouse models of atherosclerosis, human plaque leukocytes were dominated by several T-cell phenotypes with transcriptional hallmarks of T-cell activation and memory formation, T-cell receptor-, and pro-inflammatory signaling. Only mice at the age of 22 months partially resembled the activated T-cell phenotype. In a validation cohort of 43 patients undergoing carotid endarterectomy, the abundance of activated immune cell subsets in the plaque defined by multi-color flow cytometry associated with the extend of clinical atherosclerosis.
CONCLUSIONS CONCLUSIONS
Integrative scRNA-seq reveals a substantial difference in the immune cell composition of murine and human carotid atherosclerosis - a finding that questions the translational value of standard mouse models for adaptive immune cell studies. Clinical associations suggest a specific role for T-cell driven (auto-) immunity in human plaque formation and -instability.

Identifiants

pubmed: 39041203
pii: 7718334
doi: 10.1093/cvr/cvae154
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

Auteurs

Hauke Horstmann (H)

Department of Cardiology and Angiology I, Medical Center, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Department of Medicine, Division of Cardiology, NYU Cardiovascular Research Center, NYU Grossmann School of Medicine, New York, NY, USA.

Nathaly Anto Michel (NA)

Department of Cardiology, University Heart Center Graz, Medical University Graz, Austria.

Xia Sheng (X)

Department of Cardiology and Angiology I, Medical Center, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Sophie Hansen (S)

Department of Cardiology and Angiology I, Medical Center, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Alexandra Lindau (A)

Department of Cardiology and Angiology I, Medical Center, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Katharina Pfeil (K)

Department of Medicine, Division of Cardiology, NYU Cardiovascular Research Center, NYU Grossmann School of Medicine, New York, NY, USA.

Marbely C Fernández (MC)

Institute for Experimental Cardiovascular Medicine, Heart Centre, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Timoteo Marchini (T)

Department of Cardiology and Angiology I, Medical Center, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Holger Winkels (H)

Department of Cardiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Lucia Sol Mitre (LS)

Department of Cardiology and Angiology I, Medical Center, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Spemann Graduate School of Biology and Medicine (SGBM), University of Freiburg, Germany.

Tijani Abogunloko (T)

Department of Cardiology and Angiology I, Medical Center, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Spemann Graduate School of Biology and Medicine (SGBM), University of Freiburg, Germany.

Xiaowei Li (X)

Department of Cardiology and Angiology I, Medical Center, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Timothy Bon-Nawul Mwinyella (TB)

Department of Cardiology and Angiology I, Medical Center, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Mark Colin Gissler (MC)

Department of Cardiology and Angiology I, Medical Center, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Heiko Bugger (H)

Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Department of Cardiology, University Heart Center Graz, Medical University Graz, Austria.

Timo Heidt (T)

Department of Cardiology and Angiology I, Medical Center, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Konrad Buscher (K)

Department of Medicine, Division of General Internal Medicine, Nephrology and Rheumatology, University Hospital of Münster, Germany.

Ingo Hilgendorf (I)

Department of Cardiology and Angiology I, Medical Center, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Peter Stachon (P)

Department of Cardiology and Angiology I, Medical Center, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Sven Piepenburg (S)

Department of Cardiology and Angiology I, Medical Center, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Nicolas Verheyen (N)

Department of Cardiology, University Heart Center Graz, Medical University Graz, Austria.

Thomas Rathner (T)

Department of Cardiology, University Heart Center Graz, Medical University Graz, Austria.

Teresa Gerhardt (T)

Department of Cardiology, Angiology and Intensive Care Medicine CBF, Deutsches Herzzentrum der Charité, and Berlin Institute of Health (BIH), Berlin, Germany.
DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Germany.
Cardiovascular Research Institute and the Department of Medicine, Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY.

Patrick Malcolm Siegel (PM)

Department of Cardiology and Angiology I, Medical Center, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Wolfgang Kurt Oswald (WK)

Department of Vascular Surgery, Medical University Graz, Austria.

Tina Cohnert (T)

Department of Vascular Surgery, Medical University Graz, Austria.

Alma Zernecke (A)

Institute of Experimental Biomedicine, University Hospital Würzburg, Würzburg, Germany.

Josef Madl (J)

Institute for Experimental Cardiovascular Medicine, Heart Centre, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Peter Kohl (P)

Institute for Experimental Cardiovascular Medicine, Heart Centre, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Amanda C Foks (AC)

Leiden Academic Centre for Drug Research, Division of BioTherapeutics, Leiden University, Leiden, The Netherlands.

Constantin von Zur Muehlen (C)

Department of Cardiology and Angiology I, Medical Center, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Dirk Westermann (D)

Department of Cardiology and Angiology I, Medical Center, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Andreas Zirlik (A)

Department of Cardiology, University Heart Center Graz, Medical University Graz, Austria.

Dennis Wolf (D)

Department of Cardiology and Angiology I, Medical Center, University of Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Classifications MeSH